Centrum MOVEMENT & MOBILITY

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

glucosamine sulfate sodium chloride, Quantity: 942.02 mg (Equivalent: glucosamine sulfate, Qty 750 mg); bovine sodium chondroitin sulfate, Quantity: 553.39 mg (Equivalent: chondroitin sulfate, Qty 400 mg); manganese gluconate, Quantity: 7.09 mg (Equivalent: manganese, Qty 0.875 mg); copper gluconate, Quantity: 1.79 mg (Equivalent: copper, Qty 0.25 mg)

Commercializzato da:

Haleon Australia Pty Ltd

Forma farmaceutica:

Tablet, film coated

Composizione:

Excipient Ingredients: crospovidone; magnesium stearate; Carnauba Wax; povidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin

Via di somministrazione:

Oral

Indicazioni terapeutiche:

Maintain/support collagen formation ; Maintain/support bone health ; Decrease/reduce/relieve mild joint aches and pains ; Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; Helps maintain/supports healthy joint cartilage growth/development/production ; Maintain/support joint health ; Maintain/support joint mobility/flexibility ; Decrease/reduce/relieve mild joint pain/soreness

Dettagli prodotto:

Visual Identification: ;

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2020-11-05